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Background
A major issue in the management of cancer is the devel-
opment of drug resistance. In metastatic melanoma bear-
ing V600 mutations in the BRAF oncogene, all patients
undergo disease relapse after combination therapy with
BRAF and MEK inhibitors. Hence, understanding the
mechanisms at the basis of development of resistance is
fundamental to the discovery of new therapeutic
approaches. In our group we have spent the last years to
identify mechanisms of early adaptation of BRAF
mutated melanoma to BRAF and or MEK inhibitors. We
have recently shown that the ErbB3 receptor is involved
in the activation of an early feedback survival loop upon
cell exposure to BRAF and/or MEK inhibitors. Upregula-
tion of pErbB3, due to enhanced production of its ligand
neuregulin-1 (HRG), causes increased AKT phosphoryla-
tion and cell survival. Furthermore, we demonstrated
that activation of the ErbB3/AKT axis is abrogated by co-
treatment with anti-ErbB3 mAbs previously generated in
our laboratory.
Materials and methods
Eleven different melanoma cell lines bearing BRAF V600E
or BRAF V600D or BRAF V600R mutations were exposed
to short term or long term treatment with vemurafenib
and/or trametinib and/or anti ErbB3 antibodies A3 and
A4. Short term growth inhibition was measured by colony
forming assays, cell cycle and apoptosis markers. Long
term treatments allowed the selection of resistant clones.
Western blot analysis was performed on total protein
extracts using anti-ErbB3, anti-AKT and anti-ERK 1/2
antibodies. Mouse xenograft studies were carried out with
M14 cells injected s.c. at the dose of 5x 106 cells. Indivi-
dual or combined drug treatments began when tumors
reached a mean volume of 100mm3 and tumor growth
was measured by caliper.
Results
We show that ErbB3 undergoes a strong upregulation of
its phosphorylation in the absence of external addition of
neuregulin (HRG) upon exposure to vemurafenib or tra-
metinib or both drugs in the 10 out of 11 of cell lines
tested. Phospho ErbB3 activation is accompanied by
strong phosphorylation of downstream AKT. Most impor-
tantly anti-ErbB3 monoclonal antibodies combination
strongly enhances the ability of BRAF/MEK inhibitors to
silence the oncogenic MAPK and AKT pathways. This
results in potentiation of growth inhibition and of apopto-
sis compared to single antibody treatments. Moreover
ErbB3 mAbs impair the establishment of resistance and
restore drug sensitivity to vemurafenib in resistant mela-
noma cells. Finally anti-ErbB3 mAbs A3 and A4 combina-
tion strongly affect “in vivo” melanoma cell growth and
reduces tumor relapse when combined with vemurafenib
and tramentinib.
Conclusions
Feedback activation of ErbB3/AKT phosphorylation is a
fast and common response of melanoma cells to BRAF
and/or MEK inhibitors. Here, we show for the first time
that the ErbB3 receptor is a key-player also in long-time
drug establishment of resistance. These data strongly
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underline the role of ErbB3 in the rebound of melanoma
cell growth following vemurafenib/trametinib treatments
and pave the way for the use of anti-ErbB3 mAbs as
adjuncts to current target therapies in order to obtain a
durable control of tumor growth.
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